PTC Therapeutics initiates confirmatory phase III clinical trial of Translarna

The Phase III confirmatory trial is referred to as ACT CF (ataluren confirmatory trial in cystic fibrosis) and the primary endpoint is lung function as measured by relative change in percent predicted forced expiratory volume in one second, or FEV1. Read more

2 Jul 2014 12:03 News